Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Jun. 30, 2022
Current assets:    
Cash and cash equivalents $ 127,282 $ 172,567
Short-term available-for-sale investments 29,915 74,462
Accounts receivable, less allowance for doubtful accounts of $3,491 and $2,568, respectively 216,415 194,548
Inventories 169,464 141,123
Other current assets 27,920 22,856
Total current assets 570,996 605,556
Property and equipment, net 223,571 223,242
Right of use asset 97,976 65,556
Goodwill 870,542 822,101
Intangible assets, net 553,257 531,522
Other assets 283,354 46,828
Total assets 2,599,696 2,294,805
Current liabilities:    
Trade accounts payable 27,120 33,865
Salaries, wages and related accruals 38,518 61,953
Accrued expenses 15,641 17,886
Contract liabilities 24,878 23,406
Income taxes payable 18,168 13,237
Operating lease liabilities - current 10,723 11,928
Contingent consideration payable 5,250  
Current portion of long-term debt obligations   12,500
Other current liabilities 865 1,243
Total current liabilities 141,163 176,018
Deferred income taxes 94,607 98,994
Long-term debt obligations 370,000 243,410
Long-term contingent consideration payable   5,000
Operating lease liabilities 93,267 58,133
Other long-term liabilities 10,973 12,239
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,339,318 and 156,644,212, respectively 1,573 1,566
Additional paid-in capital(1) 715,052 652,467
Retained earnings(1) 1,246,612 1,122,937
Accumulated other comprehensive loss (73,551) (75,200)
Total Bio-Techne's shareholders' equity 1,889,686 1,701,770
Noncontrolling interest   (759)
Total shareholders' equity 1,889,686 1,701,011
Total liabilities and shareholders' equity $ 2,599,696 $ 2,294,805